Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 9481Neoplasms 6589Prostatic Neoplasms 4399Colorectal Neoplasms 3978Lung Neoplasms 3644Carcinoma, Non-Small-Cell Lung 3585Pancreatic Neoplasms 2479Carcinoma, Hepatocellular 2413Leukemia, Myeloid, Acute 2265Multiple Myeloma 2121Stomach Neoplasms 2109Neoplasm Metastasis 1911Head and Neck Neoplasms 1870Ovarian Neoplasms 1773Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Lymphoma 1730Brain Neoplasms 1702Rectal Neoplasms 1676Melanoma 1656Colonic Neoplasms 1629Leukemia 1500Uterine Cervical Neoplasms 1499Recurrence 1486Esophageal Neoplasms 1312Glioblastoma 1308Lymphoma, Non-Hodgkin 1205Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1109Urinary Bladder Neoplasms 1078Lymphoma, Follicular 1067

Interventions

spartalizumab 1Immunotherapy 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Objective Response Rate × Clear all
NCT03892577 2023-03-29

Real-world Study for Patients With Advanced Hepatobiliary Tumors

Peking Union Medical College Hospital

Unknown
3,000 enrolled

Objective Response Rate

NCT05760196 2023-03-08

Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors

Renmin Hospital of Wuhan University

Phase 2 Unknown
56 enrolled

Objective Response Rate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡